About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Revolutionize Preclinical Drug Candidate Discovery with Syntekabio

--News Direct--

Syntekabio (KOSDAQ: 226330), an artificial intelligence (AI) drug discovery and development company headquartered in South Korea, announced today the launch of its cost-effective AI-based total solution service for finding new drug candidates. STB CLOUD works as a comprehensive one-stop solution built on Syntekabio's own proprietary AI platform DeepMatcher®, powered by supercomputing technology. The total solution supports auto-hit-discovery, auto-lead-generation, auto-ADMET/PK (at task), and PGx biomarker for drug labeling.

Using deep-learning analysis and automatic molecular dynamics (MD) simulation technology for target proteins, the solution generates pre-stage, pre-clinical candidates within two years, including the completion of animal testing. This process drastically shortens the period before pre-clinical trials to two years from what averages to be up to seven years in traditional drug development.

Generally, it takes three to four years for candidate discovery and screening, one to three years for optimization, and the same length for non-clinical and toxicity tests. Adding five to six years for clinical trials and a couple more years for commercialization, the time it takes for full drug development from discovery can last many years causing the development price tag to go up while losing potential return on investment. Furthermore, Traditional new drug development can cost more than 10 million dollars until pre-clinical trials. Syntekabio’s STB CLOUD not only saves time but achieves substantial cost savings as it is set at only two million dollars for the entire cycle of drug development.

“Using our AI-based STB CLOUD and supercomputing technology, we have created an optimal environment for servicing the global biopharma industry,” CEO of Syntekabio, Jongsun Jung, said. “The fully automated technology covers toxicity, metabolism and pharmacokinetics prediction and will provide in the near future an automated total service for each individual model. It’s only a matter of time to automatically produce drugs with high unmet needs, including rare disease treatments.”

Currently, Syntekabio is conducting two studies in the area of auto-ADMET/PK (at task). The first is about toxicity and metabolism caused by protein binding, which is modeled based on the 3D convolutional neural network (3D-CNN). The second study is on passive delivery and permeability due to the physical and chemical properties of the compound itself, which will be implemented with pre-trained generative transformers models, such as GPT-2, using large-scale compound databases.

Syntekabio’s new drug discovery solutions will be unveiled at the 2023 BIO International Convention in Boston, June 5-8 at booth #2785. Contact Ellie Woo at ellie.woo@syntekabio.com or +1 (917) 257-4533 to request one-on-one meeting.

###

About Syntekabio

Syntekabio is a global artificial intelligence (AI) and big data-based drug discovery and development company, headquartered in South Korea since 2009, with U.S. operations bringing innovative technologies and science to create transformative medicines worldwide that are compliant with international standards to cure diseases and improve people's lives. Find out more about DeepMatcher®, NEO-ARS™, NGS-ARS™ and PGM-ARS™ at STB CLOUD (syntekabio.com)

Media Contact

Syntekabio USA

Email: admin.usa@syntekabio.com

Tel: +1 212-371-2544

Contact Details

Syntekabio inc.

Ellie Woo

+1 212-371-2544

admin.usa@syntekabio.com

Company Website

https://cloud.syntekabio.com/main

View source version on newsdirect.com: https://newsdirect.com/news/revolutionize-preclinical-drug-candidate-discovery-with-syntekabio-880707715

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.